Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1993-11-19
1998-06-09
Loring, Susan A.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241431, 4241451, 4241581, 4241781, 435325, 5303873, 53038824, 53038822, 5303887, A61K 39395, C12N 508, C12N 512, C07K 1618
Patent
active
057629307
ABSTRACT:
Bispecific molecules which react both with an Fc.gamma. receptor for immunoglobulin G (IgG) of human effector cells and with either human low density lipoprotein (LDL), or fragment thereof, or human high density lipoprotein (HDL), or a fragment thereof, are disclosed. The bispecific molecules bind to an Fc.gamma. receptor without being blocked by the binding of IgG to the same receptor. The bispecific molecules having a binding specificity for human LDL are useful for targeting human effector cells for degradation of LDL in vivo. The bispecific molecules of the present invention which have a binding specificity for human HDL are useful for targeting human HDL to human effector cells such that the HDL takes up cholesterol from the effector cells. Also disclosed are methods of treating atherosclerosis using these bispecific molecules.
REFERENCES:
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 4676980 (1987-06-01), Segal et al.
patent: 4900726 (1990-02-01), Tipton et al.
patent: 4900744 (1990-02-01), Billheimer et al.
patent: 4954617 (1990-09-01), Fanger et al.
patent: 5196324 (1993-03-01), Bumol et al.
Steinberg, D. et al, NEJM, 320 (14):915-924, Apr. 6, 1989.
Gibbs, W. Wayt, "Try, Try Again", Science and Business, Scientific American, (Jul. 1993), pp. 101-103.
Badimon et al., "Role of High Density Lipoproteins in the Regression of Atherosclerosis", Supplement to Circulation, Progression-Regression of Atherogenesis: Molecular, Cellular and Clinical Bases, American Heart Association, vol. 86, No. 6, pp. III-86-III-93 (Dec. 1992).
Morganelli et al., "Redirected Targeting of LDL to Human Monocyte Fc.sub..lambda. Receptors with Bispecific Antibodies", Arteriosclerosis and Thrombosis, vol. 12, No. 10, pp. 1131-1138 (Oct. 1992).
Mabondzo et al., "Bispecific Antibody Targeting of Human Immunodeficiency Virus Type 1 (HIV-1) Glycoprotein 41 to Human Macrophages through the Fc IgG Receptor I Mediates Neutralizing Effects in HIV-1 Infection", The Journal of Infectious Diseases, vol. 166, pp. 93-99 (Jul. 1992).
Ball et al., "Initial Trial of Bispecific Antibody-Mediated Immunotherapy of CD15-Bearing Tumors: Cytotoxicity of Human Tumor Cells Using a Bispecific Antibody Comprised of Anti-CD115 (MoAb PM81) and Anti-CD64/Fc.sub..lambda. RI (MoAb 32)", Journal of Hematotherapy, vol. 1, pp. 85-94 (1992).
Fanger, Michael W., "Bispecific Antibodies", Critical Reviews in Immunology, vol. 12, No. 3-4, pp. 101-124 (1992).
Connor et al., "Fc Receptors for IgG (Fc.sub..lambda. Rs) on Human Monocytes and Macrophages are not infectivity Receptors for Human Immunodeficiency Virus Type 1 (HIV-1): Studies using Bispecific Antibodies to Target HIV-1 to Various Myeloid Cell Surface molecules, including the Fc.sub..lambda. R", Proc. Natl. Acad. Sci., USA, vol. 88, pp. 9593-9597 (Nov. 1991).
Fanger, et al., "Bispecific Antibodies for Targeted Cellular Cytotoxicity", Trends in Biotechnology, vol. 9, pp. 375-380, (Nov. 1991).
Lopes-Virella et al., "Enhanced Uptake and Impaired Intracellular Metabolism of Low Density Lipoprotein Complexed with Anti-Low Density Lipoprotein Antibodies", Arteriosclerosis and Thrombosis, vol. 11, No. 5, pp. 1356-1367 (Sep./Oct. 1991).
Berg et al., "Bispecific Antibodies that Mediate Killing of Cells Infected with Human Immunodeficiency Virus of any Strain", Proc. Natl. Acad. Sci. USA, vol. 88, pp. 4723-4727 (Jun. 1991).
Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy", Science, vol. 252, pp. 1657-1662 (Jun. 1991).
Clark et al., "Use of Bispecific Monoclonal Antibodies to Treat Hematological Malignancies: A Model System using CD3 Transgenic Mice", Bispecific Antibodies and Targeted Cellular Cytotoxity, Second International Conference, Seillac, France, pp. 243-247 (Oct. 9-13, 1990).
de Leij et al., "Intrapleural and Intraperitoneal Application of Bispecific Antibody Retargeted Lymphocytes to Cancer Patients", Bispecific Antibodies and Targeted Cellular Cytotoxicity, Second International Conference, Seillac, France, pp. 249-251 (Oct. 9-13, 1990).
Garrido et al., "Targeting Human T-Lymphocytes with Bispecific Antibodies to Rreact against Human Ovarian Carcinoma Cells in nu
u Mice", Cancer Research, vol. 50, pp. 4227-4232 (Jul. 15, 1990).
Nitta et al., "Preliminary Trial of Specific Targeting Therapy against Malignant Glioma", The Lancet, pp. 368-371 (Feb. 17, 1990).
Araki, Norie et al., "Microquantification of Cholesterol and Cholesteryll Esters in Rat Peritoneal Macrophages by Reverse-Phase High-Performance Liquid Chromatography", Analytical Biochemistry, vol. 185, pp. 339-345 (1990).
Karawajew, L. et al., "Flow sorting of hybrid hybridomas using the DNA stain Hoechst 33342", Journal of Immunological Methods, vol. 129, pp. 277-282 (1990).
Graziano et al., "Fc.sub..lambda. R-Mediated Killing by Eosinophils", The Journal of Immunology, vol. 142, pp. 230-235 (Jan. 1, 1989).
Fanger, Michael W. et al., "Cytotoxity Mediated by Human Fc Receptors for IgG", Immunology Today, vol. 10, No. 3 (1989).
Gilliland et al., "Universal Bispecific Antibody for Targeting Tumor Cells for Destruction by Cytotoxic T Cells", Proc. Natl. Acad. Sci. USA, vol. 85, pp. 7719-7723 (Oct. 1988).
Griffith et al., "Low Density Lipoprotein Metabolism by Human Macrophages Activated with Low Density Lipoprotein Immune Complexes--A Possible Mechanism of Foam Cell Formation", The Journal of Experimental Medicine, vol. 168, p. 1041-1059 (Sep. 1988).
Liu et al., "Hormone Conjugated with Antibody to DC3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells", Science, vol. 239, pp. 395-398 (Jan. 22, 1988).
Titus et al., "Human K/Natural Killer Cells Targeted with Hetero-Cross-Linked Antibodies Specifically Lyse Tumor Cells In Vitro and Prevent Tumor Growth il Vivo", The Journal of Immunology, vol. 139, No. 9, pp. 31153-3158 (Nov. 1, 1987).
Shen et al., "Polymorphonuclear Leukocyte Function Triggered through the High Affinity Fc Receptor for Monomeric IgG", The Journal of Immunology, vol. 139, pp. 139, pp. 534-538 (Jul. 15, 1987).
Titus et al., "Human T Cells Targeted with Anti-T3 Cross-Linked to Antitumor Antibody Prevent Tumor Growth in Nude Mice", The Journal of Immunology, vol. 138, No. 11, pp. 4018-4022 (Jun. 1, 1987).
Shen, et al., "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG Mediates Cytotoxicity by Human Monocytes that is Enhanced by Interferon-.sub..lambda. and is not Blocked by Human IgG", The Journal of Immunology, vol. 137, pp. 3378-3382 (Dec. 1, 1986).
Anderson et al., "Monoclonal Antibodies to Fc Receptors for IgG on Human Mononuclear Phagocytes", The Journal of Biological Chemistry, vol. 261, No. 27, pp. 12856-12864 (Sep. 25, 1986).
Looney et al., "Human Monocytes and U937 Cells Bear Two Distinct Fc Receptors for IgG", The Journal of Immunology, vol. 136, No. 5, pp. 1641-1647 (Mar. 1, 1986).
Lubeck et al., "The Interaction of Murine IgG Subclass Proteins with Human Monocyte Fc Receptors", The Journal of Immunology, vol. 135, No. 2, pp. 1299-1304 (Aug. 1985).
Karpovsky et al., "Production of Target-Specific Effector Cells using Hetero-Cross-Linked Aggregaes Containing Anti-Target Cell and Anti-Fc.sub..lambda. Receptor Antibodies", Journal of Experimental Medicine, vol. 160, pp. 1686-1701 (Dec. 1984).
Castelli, et al., "HDL Cholesterol and Other Lipids in Coronary Heart Disease--the Cooperative Lipoprotein Phenotyping Study", Circulation, An Official Journal of the American Heart Association, Inc., vol. 55, No. 5, pp. 767-772 (May 1977).
Fanger, M. W. et al., Proceedings of the American Association for Cancer Research, 32:489-490, Mar. 1991.
Waldmann, T. A., Science, 252: 1657-1662, Jun. 1991.
Fanger Michael W.
Morganelli Peter M.
LandOfFree
Bispecific reagents for redirected targeting of human lipoprotei does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bispecific reagents for redirected targeting of human lipoprotei, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific reagents for redirected targeting of human lipoprotei will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2195857